Article ; Online: Targeting hub genes and pathways of innate immune response in COVID-19: A network biology perspective.
International journal of biological macromolecules
2020 Volume 163, Page(s) 1–8
Abstract: ... repurposing in COVID-19. Our network centric analysis suggests that moderating the innate immune response is ... of the immune response to SARS-CoV-2 will be important to develop therapeutics against COVID-19. Here, we have used ... biology approach to generate human-virus interactome. Network topological analysis discovers 15 SARS-CoV-2 ...
| Abstract | The current pandemic of 2019 novel coronavirus disease (COVID-19) caused by a novel virus strain, 2019-nCoV/SARS-CoV-2 have posed a serious threat to global public health and economy. It is largely unknown how the human immune system responds to this infection. A better understanding of the immune response to SARS-CoV-2 will be important to develop therapeutics against COVID-19. Here, we have used transcriptomic profile of human alveolar adenocarcinoma cells (A549) infected with SARS-CoV-2 and employed a network biology approach to generate human-virus interactome. Network topological analysis discovers 15 SARS-CoV-2 targets, which belongs to a subset of interferon (IFN) stimulated genes (ISGs). These ISGs (IFIT1, IFITM1, IRF7, ISG15, MX1, and OAS2) can be considered as potential candidates for drug targets in the treatments of COVID-19. We have identified significant interaction between ISGs and TLR3 agonists, like poly I: C, and imiquimod, and suggests that TLR3 agonists can be considered as a potential drug for drug repurposing in COVID-19. Our network centric analysis suggests that moderating the innate immune response is a valuable approach to target COVID-19. |
|---|---|
| MeSH term(s) | A549 Cells ; Antiviral Agents/pharmacology ; Betacoronavirus/genetics ; Betacoronavirus/immunology ; COVID-19 ; Coronavirus Infections/genetics ; Coronavirus Infections/immunology ; Coronavirus Infections/virology ; Drug Repositioning ; ELAV-Like Protein 2/genetics ; ELAV-Like Protein 2/immunology ; ELAV-Like Protein 2/metabolism ; Gene Regulatory Networks ; Humans ; Immunity, Innate ; Interferon-gamma/immunology ; Interferon-gamma/pharmacology ; Pandemics ; Pneumonia, Viral/genetics ; Pneumonia, Viral/immunology ; Pneumonia, Viral/virology ; Protein Interaction Maps/genetics ; SARS-CoV-2 ; Signal Transduction ; Transcriptome |
| Chemical Substances | Antiviral Agents ; ELAV-Like Protein 2 ; ELAVL2 protein, human ; Interferon-gamma (82115-62-6) |
| Keywords | covid19 |
| Language | English |
| Publishing date | 2020-06-26 |
| Publishing country | Netherlands |
| Document type | Journal Article |
| ZDB-ID | 282732-3 |
| ISSN | 1879-0003 ; 0141-8130 |
| ISSN (online) | 1879-0003 |
| ISSN | 0141-8130 |
| DOI | 10.1016/j.ijbiomac.2020.06.228 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.B 2374: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.